Abstract
AbstractIn recent years, research on the Cu-64 effects on malignant tumours has increased, leading to the development of radiopharmaceuticals with higher selectivity, aiming to target tumour cells while preserving healthy body cells. This work aims to assess the quality of two DOTA-derivatized neuropeptides, NMN and NT (8-13) radiolabelled with Cu-64. An improved analytical radio-HPLC method was developed to evaluate the radiochemical purity and stability. The radiochemical purity is > 99.95% for both 64Cu-DOTA-NMN and 64Cu-DOTA-NT (8-13), the radiolabelled molecules being stable for 72 h after synthesis.
Funder
Ministerul Cercetării, Inovării şi Digitalizării
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Niculae D, Dusman R, Leonte RA, Chilug LE, Dragoi CM, Nicolae A et al (2021) Biological pathways as substantiation of the use of copper radioisotopes in cancer theranostics. Front Phys 8:1–8
2. Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S et al (2019) 64Cu-based radiopharmaceuticals in molecular imaging. Technol Cancer Res Treat 18:1–10
3. Anderson CJ, Ferdani R (2009) Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 24:379–393
4. Leonte RA, Cocioabă D, Chilug LE, Băruță (Ilie) SI, Eșanu TR, Burghelea B, et al (2020) Process validation for production of copper radioisotopes in a TR-19 variable energy cyclotron. AIP Conference Proceedings 2295. 020022:1–7
5. Wadas T, Wong E, Weisman G, Anderson C (2007) Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 13:3–16